stoxline Quote Chart Rank Option Currency Glossary
  
Cingulate Inc. (CING)
1.34  -0.005 (-0.37%)    03-01 15:59
Open: 1.33
High: 1.5
Volume: 612,448
  
Pre. Close: 1.345
Low: 1.15
Market Cap: 5(M)
Technical analysis
2024-03-01 4:51:29 PM
Short term     
Mid term     
Targets 6-month :  3.95 1-year :  5.67
Resists First :  3.38 Second :  4.86
Pivot price 1.15
Supports First :  1 Second :  0.83
MAs MA(5) :  1.2 MA(20) :  1.18
MA(100) :  5.3 MA(250) :  12.56
MACD MACD :  -0.7 Signal :  -0.9
%K %D K(14,3) :  70.6 D(3) :  53.9
RSI RSI(14): 38
52-week High :  38.2 Low :  1
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CING ] has closed It is unclear right now based on current values. 92.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.5 - 1.51 1.51 - 1.51
Low: 1.14 - 1.14 1.14 - 1.15
Close: 1.33 - 1.34 1.34 - 1.35
Company Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Headline News

Wed, 28 Feb 2024
Should You Buy Cingulate Inc (CING) Stock After it Is Higher By 13.89% in a Week? - InvestorsObserver

Tue, 27 Feb 2024
Cingulate Inc (CING) Down 3.81% in Premarket Trading - InvestorsObserver

Thu, 22 Feb 2024
Premarket Mover: Cingulate Inc (CING) Up 8.33% - InvestorsObserver

Tue, 06 Feb 2024
Should You Hold Cingulate Inc (CING) Stock Tuesday Morning? - InvestorsObserver

Tue, 06 Feb 2024
Cingulate Announces Closing of $7.5 Million Public Offering - Yahoo Finance

Thu, 28 Dec 2023
Cingulate’s stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 1 (M)
Held by Insiders 8.8 (%)
Held by Institutions 10.1 (%)
Shares Short 117 (K)
Shares Short P.Month 385 (K)
Stock Financials
EPS -31.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.11
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -120.3 %
Return on Equity (ttm) -512.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -5.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.05
PEG Ratio 0
Price to Book value -12.19
Price to Sales 0
Price to Cash Flow -0.32
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android